期刊文献+

不同剂量阿托伐他汀钙对急性冠脉综合征患者血清sOX40L、IL-6的影响

下载PDF
导出
摘要 目的分析不同剂量阿托伐他汀钙对急性冠脉综合征患者血清可溶性OX40配体(s OX40L)、白细胞介素-6(IL-6)的影响。方法 64例急性冠脉综合征患者,均给予阿托伐他汀钙治疗,根据患者的用药剂量,将其分为小剂量组与大剂量组,各32例,均治疗1周后检测其血清s OX40L浓度、IL-6水平以及血脂情况。结果治疗后,大剂量组血清总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)等均低于小剂量组,差异具有统计学意义(P<0.05);高密度脂蛋白胆固醇(HDL-C)两组比较,差异无统计学意义(P>0.05);且治疗前,两组患者s OX40L、IL-6比较,差异无统计学意义(P>0.05);治疗后,大剂量组s OX40L、IL-6水平明显低于小剂量组,差异具有统计学意义(P<0.05)。结论阿托伐他汀钙治疗急性冠脉综合征患者的临床效果显著,且在一定范围内,大剂量的阿托伐他汀钙药物作用更好。
出处 《中国现代药物应用》 2015年第17期97-98,共2页 Chinese Journal of Modern Drug Application
  • 相关文献

参考文献4

二级参考文献40

  • 1Yan JC, Liu DM, Wang CP, et al. Increased levels of soluble and membrane-bound OX40 ligand in patients with acute coronary syndrome. Biomed Pharmacother, 2008, Sep 17.
  • 2Liu DM,Yan JC, Wang CP, et al. The clinical implications of increased OX40 ligand expression in patients with acute coronary syndrome. Clin Chim Acta, 2008, 397:22-26.
  • 3van Wanrooij EJ, van PuijveldeGH, de Vos P, et al. Interruption of theTnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol, 2007, 27 : 204- 210.
  • 4Ria M,Eriksson P, Boquist S, et al. Human genetic evidence that OX40 is implicated in myocardial infarction. Biochem Biophys Res Commun, 2006, 339 : 1001-1006.
  • 5Wojnicz R,Wilczek K, Nowalany-Kozielska E, et al. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol, 2006, 97:899-904.
  • 6Ludwig A,Friedel B, Metzkow S, et al. Effect of statins on the proteasomal activity in mammalian endothelial and vascular smooth muscle cells. Biochem Pharmaeol, 2005, 70:520-526.
  • 7Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med, 2000, 343: 1139-1147.
  • 8RidkerPM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 1998, 98:839-844.
  • 9Ridker PM,Danielson E, Fonseca FA, et al. Reduction in C- reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet, 2009, 373 : 1147-1148.
  • 10Simona Kirbi?,Ur?ka D. Breskvar,Mi?o ?abovi?,Igor Zupan,Andreja Sinkovi?.Inflammation markers in patients with coronary artery disease – comparison of intracoronary and systemic levels[J]. Wiener klinische Wochenschrift . 2010 (2)

共引文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部